Cargando…
Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series
BACKGROUND: Patient-reported health-related quality of life (HRQOL) differs between treatment options for prostate carcinoma. Long-term HRQOL data in brachytherapy series are scarce. Therefore, we analyzed prostate-specific and general HRQOL in patients treated with brachytherapy for prostate carcin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778674/ https://www.ncbi.nlm.nih.gov/pubmed/29357874 http://dx.doi.org/10.1186/s12955-018-0844-8 |
_version_ | 1783294400017727488 |
---|---|
author | Buergy, Daniel Schneiberg, Vincent Schaefer, Joerg Welzel, Grit Trojan, Lutz Bolenz, Christian Wenz, Frederik |
author_facet | Buergy, Daniel Schneiberg, Vincent Schaefer, Joerg Welzel, Grit Trojan, Lutz Bolenz, Christian Wenz, Frederik |
author_sort | Buergy, Daniel |
collection | PubMed |
description | BACKGROUND: Patient-reported health-related quality of life (HRQOL) differs between treatment options for prostate carcinoma. Long-term HRQOL data in brachytherapy series are scarce. Therefore, we analyzed prostate-specific and general HRQOL in patients treated with brachytherapy for prostate carcinoma after long-term follow-up. METHODS: Two hundred ninety-six patients with prostate carcinoma were treated with brachytherapy (01/1998–11/2003). General and prostate-specific HRQOL were measured using EORTC-QLQ-C30 and EORTC-QLQ-PR25, respectively. Patients were asked to complete the questionnaires after a median follow-up of 141 (119–181) months. QLQ-C30 results were compared to the German reference population. QLQ-PR25 results were compared to an earlier follow-up after a median of 51 months (no published QLQ-PR25 reference population for comparison). Additionally, a literature review on HRQOL data in brachytherapy series was performed. RESULTS: One hundred six (35.8%) patients were lost to follow-up, 70 (23.6%) had died. 120 (40.5%) patients were contacted. 80 questionnaires were returned (27% of the original cohort; 91% of alive patients were ≥70 years). Sexual activity declined over time (mean scores: 40.5 vs. 45.5; p = 0.006), hormonal treatment-related symptoms, problems associated with incontinence aids, and burden of obstructive urinary symptoms did not differ significantly compared to the 51-month follow-up. General HRQOL was numerically better in our cohort as compared to the German reference population (> 16% relative difference for both age strata; < 70 and ≥70 years). CONCLUSIONS: Our results indicate that symptom-burden after long-term follow-up and associated prostate-specific HRQOL remains relatively stable from 51 to 141 months. General HRQOL in surviving patients was numerically better compared to the reference population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-018-0844-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5778674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57786742018-01-31 Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series Buergy, Daniel Schneiberg, Vincent Schaefer, Joerg Welzel, Grit Trojan, Lutz Bolenz, Christian Wenz, Frederik Health Qual Life Outcomes Research BACKGROUND: Patient-reported health-related quality of life (HRQOL) differs between treatment options for prostate carcinoma. Long-term HRQOL data in brachytherapy series are scarce. Therefore, we analyzed prostate-specific and general HRQOL in patients treated with brachytherapy for prostate carcinoma after long-term follow-up. METHODS: Two hundred ninety-six patients with prostate carcinoma were treated with brachytherapy (01/1998–11/2003). General and prostate-specific HRQOL were measured using EORTC-QLQ-C30 and EORTC-QLQ-PR25, respectively. Patients were asked to complete the questionnaires after a median follow-up of 141 (119–181) months. QLQ-C30 results were compared to the German reference population. QLQ-PR25 results were compared to an earlier follow-up after a median of 51 months (no published QLQ-PR25 reference population for comparison). Additionally, a literature review on HRQOL data in brachytherapy series was performed. RESULTS: One hundred six (35.8%) patients were lost to follow-up, 70 (23.6%) had died. 120 (40.5%) patients were contacted. 80 questionnaires were returned (27% of the original cohort; 91% of alive patients were ≥70 years). Sexual activity declined over time (mean scores: 40.5 vs. 45.5; p = 0.006), hormonal treatment-related symptoms, problems associated with incontinence aids, and burden of obstructive urinary symptoms did not differ significantly compared to the 51-month follow-up. General HRQOL was numerically better in our cohort as compared to the German reference population (> 16% relative difference for both age strata; < 70 and ≥70 years). CONCLUSIONS: Our results indicate that symptom-burden after long-term follow-up and associated prostate-specific HRQOL remains relatively stable from 51 to 141 months. General HRQOL in surviving patients was numerically better compared to the reference population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-018-0844-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-22 /pmc/articles/PMC5778674/ /pubmed/29357874 http://dx.doi.org/10.1186/s12955-018-0844-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Buergy, Daniel Schneiberg, Vincent Schaefer, Joerg Welzel, Grit Trojan, Lutz Bolenz, Christian Wenz, Frederik Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series |
title | Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series |
title_full | Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series |
title_fullStr | Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series |
title_full_unstemmed | Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series |
title_short | Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series |
title_sort | quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on qlq-c30 and qlq-pr25 results in published brachytherapy series |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778674/ https://www.ncbi.nlm.nih.gov/pubmed/29357874 http://dx.doi.org/10.1186/s12955-018-0844-8 |
work_keys_str_mv | AT buergydaniel qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries AT schneibergvincent qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries AT schaeferjoerg qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries AT welzelgrit qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries AT trojanlutz qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries AT bolenzchristian qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries AT wenzfrederik qualityoflifeafterlowdoseratebrachytherapyforprostatecarcinomalongtermresultsandliteraturereviewonqlqc30andqlqpr25resultsinpublishedbrachytherapyseries |